IRIS
BRESCIA MORRA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.241
EU - Europa 2.562
AS - Asia 1.641
AF - Africa 83
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 8.551
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.147
IT - Italia 1.211
SG - Singapore 879
CN - Cina 544
NL - Olanda 308
DE - Germania 246
FI - Finlandia 187
IE - Irlanda 162
UA - Ucraina 150
GB - Regno Unito 109
CA - Canada 92
IN - India 88
CI - Costa d'Avorio 80
SE - Svezia 63
IR - Iran 58
VN - Vietnam 56
FR - Francia 46
BE - Belgio 16
ES - Italia 14
BR - Brasile 13
RU - Federazione Russa 7
LT - Lituania 5
CH - Svizzera 4
GR - Grecia 4
HK - Hong Kong 4
JP - Giappone 4
PL - Polonia 4
SK - Slovacchia (Repubblica Slovacca) 4
AR - Argentina 3
AU - Australia 3
CZ - Repubblica Ceca 3
MK - Macedonia 3
PT - Portogallo 3
TH - Thailandia 3
TR - Turchia 3
AT - Austria 2
BG - Bulgaria 2
CO - Colombia 2
EU - Europa 2
HU - Ungheria 2
RO - Romania 2
RS - Serbia 2
ZA - Sudafrica 2
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BZ - Belize 1
HR - Croazia 1
IM - Isola di Man 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
QA - Qatar 1
Totale 8.551
Salva come PNG Salva come JPEG
Città #
Chandler 761
Singapore 713
Amsterdam 298
Naples 276
Ashburn 270
Millbury 249
Santa Clara 233
Princeton 180
Napoli 175
Nanjing 143
Beijing 142
Des Moines 122
Boston 97
Norwalk 85
Wilmington 81
Lawrence 74
Ottawa 70
Jacksonville 64
Dong Ket 56
Milan 56
Nanchang 48
Seattle 37
Rome 35
Krefeld 33
Hebei 30
Dublin 26
Pune 26
Tianjin 26
Jiaxing 23
Dallas 22
Augusta 20
Cava De' Tirreni 20
Shenyang 20
San Mateo 18
Washington 18
Dearborn 16
Helsinki 16
Houston 15
Rottweil 15
Toronto 15
Formia 14
Fairfield 13
Frankfurt am Main 13
Lappeenranta 13
Los Angeles 13
Munich 13
New York 13
Kronberg 12
Sant'arpino 12
Woodbridge 12
Bari 11
Guangzhou 11
Nola 11
Redwood City 11
Brussels 10
London 10
Changsha 9
Ann Arbor 8
Boardman 8
Council Bluffs 8
Falls Church 8
Springfield 8
Stockholm 8
Vermezzo 8
Faenza 7
Montalbano Jonico 7
Saint Louis 7
Salerno 7
Shenzhen 7
Bilbao 6
Caposele 6
Capri 6
Chengdu 6
San Jose 6
Torre Annunziata 6
Vicenza 6
Ardabil 5
Aversa 5
Caserta 5
Casoria 5
Indiana 5
Kunming 5
Leawood 5
Mountain View 5
Qualiano 5
Wuhan 5
Castellammare Di Stabia 4
Catania 4
Clifton 4
Forino 4
Hong Kong 4
Marsala 4
Mugnano di Napoli 4
Paris 4
Shanghai 4
Suffern 4
Trapani 4
Turin 4
Bologna 3
Boscoreale 3
Totale 5.062
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 163
Quality of Life and Cognitive function in pediatric and young adults multiple sclerosis: a cross-sectional study 131
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 75
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 74
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 72
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 72
Vascular alterations in multiple sclerosis and amyotrophic lateral sclerosis : preliminary analysis of susceptibility factors 65
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 64
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 64
SPG5 and multiple sclerosis: clinical and genetic overlap? 63
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents 61
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 61
L'attenzione alle donne nei servizi psicologici offerti dal Centro Regionale Sclerosi Multipla ''Federico II'' di Napoli: l'esperienza del progetto SIM 60
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 60
Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis 60
Quality of life and cognitive functions in early onset multiple sclerosis 59
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 59
The use of medical-grade cannabis in patients non-responders to Nabiximols 57
Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis 55
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 55
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 55
Brain atrophy and lesion load in a large population of patients with multiple sclerosis 54
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 54
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 54
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 53
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration 53
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 53
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 51
Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study 51
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 49
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 49
Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience 49
A refined physical and transcriptional map of the SPG9 locus on 10q23.3[#150]q24.2 48
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. 48
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 48
Uric acid: a potential biomarker of multiple sclerosis and of its disability 47
ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism 47
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 47
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 47
Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study 47
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 47
A refined physical and transcriptional map of the SPG9 locus on 10q23.3-q24.2. 46
A multilayer perceptron neural network-based approach for the identification of responsiveness to interferon therapy in multiple sclerosis patients 46
A randomized clinical trial of lithium in multiple system atrophy. 46
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 46
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 46
Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach 45
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 44
Can people with multiple sclerosis actually understand what they read in the Internet age? 44
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 44
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis 44
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis 44
Multiple sclerosis and headache co-morbidity. A case-control study 43
Epileptic seizures in multiple sclerosis: clinical and EEG correlations. 43
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 43
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis 43
Antiphospholipid-related chorea. 42
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). 42
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 42
Retinal vascular density in multiple sclerosis: a one year follow up 42
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis 42
Imaging of brain perfusion in multiple sclerosis and neurodegenerative disorders: association with endothelial factors. An interim analysis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 20, pp. 297-297). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 41
A longitudinal real-life comparison study of natalizumab and fingolimod 41
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery 41
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 41
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. 40
Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study 40
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 40
Mobitz type I and II atrioventricular blocks during fingolimod therapy 40
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis 40
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 40
COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak 40
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice 40
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study 39
Evaluation of optic nerve subarachnoid space in primary open angle glaucoma using ultrasound examination 39
Optical coherence tomography angiography in optic nerve sheath meningioma 39
A multiple n-glucosylated peptide epitope efficiently detecting antibodies in multiple sclerosis 39
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 39
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 38
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 38
Internal jugular vein blood flow in multiple sclerosis patients and matched controls. 38
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 38
The Framingham cardiovascular risk score in multiple sclerosis 38
Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: Results of a randomized controlled trial 38
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 38
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 38
Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? 37
Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015 36
The importance of being persistent to multiple sclerosis treatments 36
Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy? 36
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 36
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 35
Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. 35
Anti-JC virus antibodies index and JCV DNA concordance and markers of active viral replication: true exposure to JCV virus in natalizumab treated patients. In MULTIPLE SCLEROSIS JOURNAL (Vol. 19, No. 11, pp. 495-496). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 35
Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach 35
Longitudinal Assessment of Dentate Nuclei Relaxometry during Massive Gadobutrol Exposure 35
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 34
Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. 34
Vitamin D in a population of Southern Italy relapsing remitting and secondary progressive multiple sclerosis patients. 34
A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. 34
Totale 4.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.634
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.634
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020413 0 0 0 0 32 33 32 31 28 98 114 45
2020/2021698 56 39 48 87 82 64 41 9 83 16 100 73
2021/20221.355 17 2 12 16 28 78 22 58 179 117 277 549
2022/20232.217 264 177 55 110 238 256 164 173 326 318 98 38
2023/20241.609 51 240 232 104 78 184 71 163 23 38 280 145
2024/20251.354 437 453 49 128 287 0 0 0 0 0 0 0
Totale 9.223